Bhairavi Sheshadri, MD
Endocrinology, Diabetes & Metabolism · Raleigh, NCNPI 1255745188
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Cequr Corporation at 29.8% of the total. 2025 is the largest year on record at $12,933, more than ten times the $311 reported in 2019.
Across 896 payments — averaging $30.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$8K
- Medtronic$3K
- Corcept Therapeutics$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Abbott$1K
- plus $9K from 52 others
What the payments were for
- Speaking & faculty fees$9,10833%
- Travel & lodging$1,7926%
- Food & beverage$16,40659%
- Education$3281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$8,160
- Korlym$1,925
- MINIMED 770G$1,594
- TWIIST$202
- EVENITY$150
- TEPEZZA$128
- Ozempic$120
- MOUNJARO$118
- InPen$102
How this compares
$27,634 in reported general payments places this provider in the 80th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $199,054 |
| JardianceEmpagliflozin | 141 | $145,325 |
| MounjaroTirzepatide | 84 | $122,332 |
| RybelsusSemaglutide | 23 | $36,136 |
| TymlosAbaloparatide | 13 | $33,208 |
| ProliaDenosumab | 17 | $29,484 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $22,354 |
| TrulicityDulaglutide | 16 | $20,249 |
| HumatropeSomatropin | 12 | $20,064 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $16,325 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,676 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $15,495 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $13,684 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,559 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $11,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,002 | $235,190183 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humatrope, Lyumjev | $1,877 | $170,660126 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $361 | $167,679166 claims |
| Radius Health, Inc.Tymlos | $546 | $33,20813 claims |
| AmgenProlia | $808 | $29,48417 claims |
| MerckJanumet Xr, Januvia | $73 | $22,13426 claims |
| AbbVieSynthroid | $567 | $5,58164 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $78 | $3,352318 claims |
| IBSA Pharma Inc.Tirosint | $513 | $2,96814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Raleigh
- Corey BerlinRaleigh$742K
- Denis BeckerRaleigh$459K
- Elizabeth HoltRaleigh$167K
- Julia Warren-UlanchRaleigh$31K
- Glenn StallRaleigh$9K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.